Top

Published in:

01-10-2019 | Original Article

CRP and LOX-1: a Mechanism for Increasing the Tumorigenic Potential of Colorectal Cancer Carcinoma Cell Line

Authors: Mousa Ghazi-Khanloosani, Ahmad Reza Bandegi, Parviz Kokhaei, Mehdi Barati, Abbas Pakdel

Published in: Pathology & Oncology Research | Issue 4/2019

Abstract

Chronic inflammation and dyslipidemia are associated with an increase in the incidence of colorectal cancer (CRC). Serum C- reactive protein (CRP) and oxidized low-density lipoprotein (oxLDL), as Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) ligands, increase during inflammation and dyslipidemia, respectively. To evaluate the effects of CRP on the expression of important genes involved in the development of CRC, the CRC cell line, LS174T, was treated with the commercial CRP. Based on the Real-time PCR data, in the presence of CRP, LOX-1, CEA, MMP1, and MMP2 mRNA expression significantly increased, compared to the control group. Moreover, in the presence of CRP, secretion, and expression of CEA in the cell lysate and conditioned media increased in a concentration-dependent manner. The results of flow cytometry showed that expression of LOX-1 receptors at the cell surface increased significantly in the presence of 10 mg/L of CRP. However, inhibition of LOX-1 receptors with a specific monoclonal antibody reduced the effects of CRP on protein/mRNA expression. In conclusion, Increased CRP level, can potentially elevate the expression of important genes in CRC by stimulating LOX-1 receptors.

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Grivennikov SI (2013) Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35(2):229–244. https://doi.org/10.1007/s00281-012-0352-6 CrossRefPubMed

Morrison WB (2012) Inflammation and cancer: a comparative view. J Vet Intern Med 26(1):18–31. https://doi.org/10.1111/j.1939-1676.2011.00836.x CrossRefPubMed

Ernst PB, Gold BD (2000) The disease spectrum of helicobacter pylori: the immunopathogenesis of gastroduodenal ulcer and gastric cancer. Annu Rev Microbiol 54:615–640. https://doi.org/10.1146/annurev.micro.54.1.615 CrossRefPubMed

Swidnicka-Siergiejko AK, Gomez-Chou SB, Cruz-Monserrate Z, Deng D, Liu Y, Huang H, Ji B, Azizian N, Daniluk J, Lu W, Wang H, Maitra A, Logsdon CD (2017) Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53. Oncogene 36(22):3149–3158. https://doi.org/10.1038/onc.2016.461 CrossRefPubMed

Rasch S, Algul H (2014) A clinical perspective on the role of chronic inflammation in gastrointestinal cancer. Clin Exp Gastroenterol 7:261–272. https://doi.org/10.2147/CEG.S43457 CrossRefPubMedPubMedCentral

Chen M, Masaki T, Sawamura T (2002) LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 95(1):89–100CrossRefPubMed

Shih HH, Zhang SW, Cao W, Hahn A, Wang J, Paulsen JE, Harnish DC (2009) CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol 296(5):H1643–H1650. https://doi.org/10.1152/ajpheart.00938.2008 CrossRefPubMed

Guo YZ, Pan L, Du CJ, Ren DQ, Xie XM (2013) Association between C-reactive protein and risk of cancer: a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev 14(1):243–248CrossRefPubMed

10.

Lin MS, Huang JX, Zhu JY, Shen HZ (2013) Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer. Exp Ther Med 6(6):1369–1374. https://doi.org/10.3892/etm.2013.1350 CrossRefPubMedPubMedCentral

11.

Pakdel A, Malekzadeh M, Naghibalhossaini F (2016) The association between preoperative serum CEA concentrations and synchronous liver metastasis in colorectal cancer patients. Cancer Biomark 16(2):245–252. https://doi.org/10.3233/Cbm-150561 CrossRefPubMed

12.

Saito G, Sadahiro S, Kamata H, Miyakita H, Okada K, Tanaka A, Suzuki T (2017) Monitoring of serum carcinoembryonic antigen levels after curative resection of Colon Cancer: cutoff values determined according to preoperative levels enhance the diagnostic accuracy for recurrence. Oncology 92(5):276–282. https://doi.org/10.1159/000456075 CrossRefPubMed

13.

Aarons CB, Bajenova O, Andrews C, Heydrick S, Bushell KN, Reed KL, Thomas P, Becker JM, Stucchi AF (2007) Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis 24(3):201–209. https://doi.org/10.1007/s10585-007-9069-7 CrossRefPubMed

14.

Gangopadhyay A, Lazure DA, Thomas P (1997) Carcinoembryonic antigen induces signal transduction in Kupffer cells. Cancer Lett 118(1):1–6. https://doi.org/10.1016/S0304-3835(97)00216-4 CrossRefPubMed

15.

Kim IH, Lee JE, Yang JH, Jeong JW, Ro S, Lee MA (2017) Clinical significance of changes in systemic inflammatory markers and carcinoembryonic antigen levels in predicting metastatic colorectal cancer prognosis and chemotherapy response. Asia-Pacific journal of clinical oncology 14:239–246. https://doi.org/10.1111/ajco.12784 CrossRefPubMed

16.

Liang M, Zhang P, Fu J (2007) Up-regulation of LOX-1 expression by TNF-alpha promotes trans-endothelial migration of MDA-MB-231 breast cancer cells. Cancer Lett 258(1):31–37. https://doi.org/10.1016/j.canlet.2007.08.003 CrossRefPubMed

17.

Khaidakov M, Mehta JL (2012) Oxidized LDL triggers pro-oncogenic signaling in human breast mammary epithelial cells partly via stimulation of MiR-21. PLoS One 7(10):e46973. https://doi.org/10.1371/journal.pone.0046973 CrossRefPubMedPubMedCentral

18.

Gonzalez-Chavarria I, Cerro RP, Parra NP, Sandoval FA, Zuniga FA, Omazabal VA, Lamperti LI, Jimenez SP, Fernandez EA, Gutierrez NA, Rodriguez FS, Onate SA, Sanchez O, Vera JC, Toledo JR (2014) Lectin-Like Oxidized LDL Receptor-1 Is an Enhancer of Tumor Angiogenesis in Human Prostate Cancer Cells PLoS One 9 (8). https://doi.org/10.1371/Journalpone.0106219 ARTN e106219

19.

Gonzalez-Chavarria I, Fernandez E, Gutierrez N, Gonzalez-Horta EE, Sandoval F, Cifuentes P, Castillo C, Cerro R, Sanchez O, Toledo JR (2017) LOX-1 activation by oxLDL triggers an epithelial mesenchymal transition and promotes tumorigenic potential in prostate cancer cells. Cancer Lett 414:34–43. https://doi.org/10.1016/j.canlet.2017.10.035 CrossRefPubMed

20.

Li C, Zhang J, Wu H, Li L, Yang C, Song S, Peng P, Shao M, Zhang M, Zhao J, Zhao R, Wu W, Ruan Y, Wang L, Gu J (2017) Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3beta activation. Sci Rep 7:45275. https://doi.org/10.1038/srep45275 CrossRefPubMedPubMedCentral

21.

Murdocca M, Mango R, Pucci S, Biocca S, Testa B, Capuano R, Paolesse R, Sanchez M, Orlandi A, di Natale C, Novelli G, Sangiuolo F (2016) The lectin-like oxidized LDL receptor-1: a new potential molecular target in colorectal cancer. Oncotarget 7(12):14765–14780. https://doi.org/10.18632/oncotarget.7430 CrossRefPubMedPubMedCentral

22.

Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, Cominacini L, Delneste Y, Matsuda H, Sawamura T (2009) Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 55(2):285–294. https://doi.org/10.1373/clinchem.2008.119750 CrossRefPubMed

23.

Rizzacasa B, Morini E, Pucci S, Murdocca M, Novelli G, Amati F (2017) LOX-1 and its splice variants: a new challenge for atherosclerosis and Cancer-targeted therapies. Int J Mol Sci 18 (2). doi:https://doi.org/10.3390/Ijms18020290 Artn 290

24.

Zampino MG, Magni E, Ravenda PS, Cella CA, Bonomo G, Della Vigna P, Galdy S, Spada F, Varano GM, Mauri G, Fazio N, Orsi F (2016) Treatments for colorectal liver metastases: a new focus on a familiar concept. Crit Rev Oncol Hematol 108:154–163. https://doi.org/10.1016/j.critrevonc.2016.11.005 CrossRefPubMed

25.

Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA (2007) Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's heart and health study. Cancer Epidemiol Biomark Prev 16(6):1155–1159. https://doi.org/10.1158/1055-9965.EPI-07-0093 CrossRef

26.

Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomark Prev 15(2):381–384. https://doi.org/10.1158/1055-9965.EPI-05-0626 CrossRef

27.

Heikkila K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61(9):824–833. https://doi.org/10.1136/jech.2006.051292 CrossRefPubMedPubMedCentral

28.

Heikkila K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, Ben-Shlomo Y, Ebrahim S, Lawlor DA (2009) Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 20(1):15–26. https://doi.org/10.1007/s10552-008-9212-z CrossRefPubMed

29.

Thomsen M, Kersten C, Sorbye H, Skovlund E, Glimelius B, Pfeiffer P, Johansen JS, Kure EH, Ikdahl T, Tveit KM, Christoffersen T, Guren TK (2016) Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. Oncotarget 7(46):75013–75022. https://doi.org/10.18632/oncotarget.12601 CrossRefPubMedPubMedCentral

30.

Woo HD, Kim K, Kim J (2015) Association between preoperative C-reactive protein level and colorectal cancer survival: a meta-analysis. Cancer Causes Control 26(11):1661–1670. https://doi.org/10.1007/s10552-015-0663-8 CrossRefPubMed

31.

Lu JJ, Mitra S, Wang XW, Khaidakov M, Mehta JL (2011) Oxidative stress and lectin-like ox-LDL-receptor LOX-1 in Atherogenesis and tumorigenesis. Antioxid Redox Signal 15(8):2301–2333. https://doi.org/10.1089/ars.2010.3792 CrossRefPubMed

32.

Zhang J, Zhang L, Li C, Yang C, Li L, Song S, Wu H, Liu F, Wang L, Gu J (2017) LOX-1 is a poor prognostic indicator and induces epithelial-mesenchymal transition and metastasis in pancreatic cancer patients. Cell Oncol (Dordr) 41:73–84. https://doi.org/10.1007/s13402-017-0360-6 CrossRef

33.

Pakdel A, Naghibalhossaini F, Mokarram P, Jaberipour M, Hosseini A (2012) Regulation of carcinoembryonic antigen release from colorectal cancer cells. Mol Biol Rep 39(4):3695–3704. https://doi.org/10.1007/s11033-011-1144-0 CrossRefPubMed

34.

Naghibalhossaini F, Ebadi P (2006) Evidence for CEA release from human colon cancer cells by an endogenous GPI-PLD enzyme. Cancer Lett 234(2):158–167. https://doi.org/10.1016/j.canlet.2005.03.028 CrossRefPubMed

35.

Kim YW, Ko YT, Kim NK, Chung HC, Min BS, Lee KY, Park JP, Kim H (2010) A comparative study of protein expression in primary colorectal cancer and synchronous hepatic metastases: the significance of matrix metalloproteinase-1 expression as a predictor of liver metastasis. Scand J Gastroenterol 45(2):217–225. https://doi.org/10.3109/00365520903453158 CrossRefPubMed

36.

Zhu XH, Wang JM, Yang SS, Wang FF, Hu JL, Xin SN, Men H, Lu GF, Lan XL, Zhang D, Wang XY, Liao WT, Ding YQ, Liang L (2017) Down-regulation of DAB2IP promotes colorectal cancer invasion and metastasis by translocating hnRNPK into nucleus to enhance the transcription of MMP2. Int J Cancer 141(1):172–183. https://doi.org/10.1002/ijc.30701 CrossRefPubMed

37.

Hirsch HA, Iliopoulos D, Joshi A, Zhang Y, Jaeger SA, Bulyk M, Tsichlis PN, Shirley Liu X, Struhl K (2010) A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 17(4):348–361. https://doi.org/10.1016/j.ccr.2010.01.022 CrossRefPubMedPubMedCentral

38.

Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369(6482):669–671. https://doi.org/10.1038/369669a0 CrossRefPubMed

39.

Ninomiya I, Yonemura Y, Matsumoto H, Sugiyama K, Kamata T, Miwa K, Miyazaki I, Shiku H (1991) Expression of c-myc gene product in gastric carcinoma. Oncology 48(2):149–153CrossRefPubMed

40.

Wang W, Xue L, Wang P (2011) Prognostic value of beta-catenin, c-myc, and cyclin D1 expressions in patients with esophageal squamous cell carcinoma. Med Oncol 28(1):163–169. https://doi.org/10.1007/s12032-010-9436-0 CrossRefPubMed

41.

Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB, Choe G, Kim WH, Lee HS (2016) Favorable prognosis in colorectal cancer patients with co-expression of c-MYC and ss-catenin. BMC Cancer 16(1):730. https://doi.org/10.1186/s12885-016-2770-7 CrossRefPubMedPubMedCentral

42.

Chu YC, Huang KT (2016) CRP/oxLDL co-incubates impair endothelial functions through CD32, LOX-1, and keratin 1 with dependence on their ratio. J Taiwan Inst Chem E 64:16–21. https://doi.org/10.1016/j.jtice.2016.03.048 CrossRef

Title: CRP and LOX-1: a Mechanism for Increasing the Tumorigenic Potential of Colorectal Cancer Carcinoma Cell Line
Authors: Mousa Ghazi-Khanloosani
Ahmad Reza Bandegi
Parviz Kokhaei
Mehdi Barati
Abbas Pakdel
Publication date: 01-10-2019
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 4/2019
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-018-0507-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Genetic Investigation of Polymorphic OGG1 and MUTYH Genes Towards Increased Susceptibility in Lung Adenocarcinoma and its Impact on Overall Survival of Lung Cancer Patients Treated with Platinum Based Chemotherapy

Up-Regulation of the Alpha Prime Subunit of Protein Kinase CK2 as a Marker of Fast Proliferation in GL261 Cultured Cells

Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program

Comparison of Capecitabine (Xeloda) vs. Combination of Capecitabine and Oxaliplatin (XELOX) as Neoadjuvant CRT for Locally Advanced Rectal Cancer

EGFR-TK1-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients with NSCLC: When Is it Worth The Risk?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer